Abstract
We detected significant levels of β-glucosidase, β-galactosidase, sialidase Neu3 and sphingomyelinase activities associated with the plasma membrane of fibroblasts from normal and Niemann-Pick subjects and of cells from breast, ovary, colon and neuroblastoma tumors in culture. All of the cells subjected to ionizing radiations showed an increase of the activity of plasma membrane β-glucosidase, β-galactosidase and sialidase Neu3, in addition of the well known increase of activity of plasma membrane sphingomyelinase, under similar conditions. Human breast cancer cell line T47D was studied in detail. In these cells the increase of activity of β-glucosidase and β-galactosidase was parallel to the increase of irradiation dose up to 60 Gy and continued with time, at least up to 72 h from irradiation. β-glucosidase increased up to 17 times and β-galactosidase up to 40 times with respect to control. Sialidase Neu3 and sphingomyelinase increased about 2 times at a dose of 20 Gy but no further significant differences were observed with increase of radiation dose and time. After irradiation, we observed a reduction of cell proliferation, an increase of apoptotic cell death and an increase of plasma membrane ceramide up to 3 times, with respect to control cells. Tritiated GM3 ganglioside has been administered to T47D cells under conditions that prevented the lysosomal catabolism. GM3 became component of the plasma membranes and was transformed into LacCer, GlcCer and ceramide. The quantity of ceramide produced in irradiated cells was about two times that of control cells.
Similar content being viewed by others
References
Hakomori, S.I.: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56, 5309–5318 (1996)
Hakomori, S.: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 99, 10231–10233 (2002)
Dennis, J.W., Granovsky, M., Warren, C.E.: Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21–34 (1999)
Moskal, J.R., Kroes, R.A., Dawson, G.: The glycobiology of brain tumors: disease relevance and therapeutic potential. Expert. Rev. Neurother. 9, 1529–1545 (2009)
Meany, D.L., Chan, D.W.: Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 8, 7 (2011)
Sonnino, S., Aureli, M., Loberto, N., Chigorno, V., Prinetti, A.: Fine tuning of cell functions through remodeling of glycosphingolipids by plasma membrane-associated glycohydrolases. FEBS Lett. 584, 1914–1922 (2010)
Aureli, M., Loberto, N., Bassi, R., Ferraretto, A., Perego, S., Lanteri, P., Chigorno, V., Sonnino, S., Prinetti, A.: Plasma membrane-associated glycohydrolases activation by extracellular acidification due to proton exchangers. Neurochem Res. (2011).
Aureli, M., Masilamani, A.P., Illuzzi, G., Loberto, N., Scandroglio, F., Prinetti, A., Chigorno, V., Sonnino, S.: Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett. 583, 2469–2473 (2009)
Valaperta, R., Valsecchi, M., Rocchetta, F., Aureli, M., Prioni, S., Prinetti, A., Chigorno, V., Sonnino, S.: Induction of axonal differentiation by silencing plasma membrane-associated sialidase Neu3 in neuroblastoma cells. J. Neurochem. 100, 708–719 (2007)
Valaperta, R., Chigorno, V., Basso, L., Prinetti, A., Bresciani, R., Preti, A., Miyagi, T., Sonnino, S.: Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J. 20, 1227–1229 (2006)
Aureli, M., Masilamani, A.P., Illuzzi, G., Loberto, N., Scandroglio, F., Prinetti, A., Chigorno, V., Sonnino, S.: Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett. 583, 2469–2473 (2009)
Aureli, M., Loberto, N., Chigorno, V., Prinetti, A., Sonnino, S.: Remodeling of sphingolipids by plasma membrane associated enzymes. Neurochem Res. (2010)
Papini, N., Anastasia, L., Tringali, C., Croci, G., Bresciani, R., Yamaguchi, K., Miyagi, T., Preti, A., Prinetti, A., Prioni, S., Sonnino, S., Tettamanti, G., Venerando, B., Monti, E.: The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J. Biol. Chem. 279, 16989–16995 (2004)
Kakugawa, Y., Wada, T., Yamaguchi, K., Yamanami, H., Ouchi, K., Sato, I., Miyagi, T.: Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U. S. A. 99, 10718–10723 (2002)
Kawamura, S., Sato, I., Wada, T., Yamaguchi, K., Li, Y., Li, D., Zhao, X., Ueno, S., Aoki, H., Tochigi, T., Kuwahara, M., Kitamura, T., Takahashi, K., Moriya, S., Miyagi, T.: Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling. Cell Death Differ. (2011)
Ost, P., Cozzarini, C., De Meerleer, G., Fiorino, C., De Potter, B., Briganti, A., Nagler, E.V.T., Montorsi, F., Fonteyne, V. r., Di Muzio, N.: High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. International Journal of Radiation Oncology*Biology*Physics
Group, I. M. R. T. C. W.: Intensity-modulated radiotherapy: current status and issues of interest. International Journal of Radiation Oncology*Biology*Physics. 51, 880–914 (2001)
Fodor, A., Fiorino, C., Dell’Oca, I., Broggi, S., Pasetti, M., Cattaneo, G., Gianolli, L., Calandrino, R., Di Muzio, N.: PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlentherapie und Onkologie. 1–8
Zelefsky, M.J., Fuks, Z.V.I., Hunt, M., Lee, H.J., Lombardi, D., Ling, C.C., Reuter, V.E., Venkatraman, E.S., Leibel, S.A.: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol. 166, 876–881 (2001)
Kolesnick, R., Fuks, Z.: Radiation and ceramide-induced apoptosis. Oncogene 22, 5897–5906 (2003)
Santana, P., Pena, L.A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E.H., Fuks, Z., Kolesnick, R.: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86, 189–199 (1996)
Gulbins, E., Kolesnick, R., Quinn, P.J., Kagan, V.E.: In: Harris, J.R., Biswas, B.B., Quinn, P., (eds.): Springer US, 2004. pp. 229–244
Obeid, L.M., Linardic, C.M., Karolak, L.A., Hannun, Y.A.: Programmed cell death induced by ceramide. Science 259, 1769–1771 (1993)
Haimovitz-Friedman, A., Kan, C.C., Ehleiter, D., Persaud, R.S., McLoughlin, M., Fuks, Z., Kolesnick, R.N.: Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med. 180, 525–535 (1994)
Sonnino, S., Chigorno, V., Tettamanti, G.: Preparation of radioactive gangliosides, 3H or 14C isotopically labeled at oligosaccharide or ceramide moieties. Methods Enzymol. 311, 639–656 (2000)
Leroy, J.G., Ho, M.W., MacBrinn, M.C., Zielke, K., Jacob, J., O’Brien, J.S.: I-cell disease: biochemical studies. Pediatr. Res. 6, 752–757 (1972)
Aureli, M., Prioni, S., Mauri, L., Loberto, N., Casellato, R., Ciampa, M.G., Chigorno, V., Prinetti, A., Sonnino, S.: Photoactivable sphingosine as a tool to study membrane microenvironments in cultured cells. J Lipid Res. 51, 798–808 (2010)
Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J., Louie, K.G., Knutsen, T., McKoy, W.M., Young, R.C., Ozols, R.F.: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414–418 (1987)
Osmak, M., Eljuga, D.: The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res Exp Med (Berl) 193, 389–396 (1993)
Appierto, V., Cavadini, E., Pergolizzi, R., Cleris, L., Lotan, R., Canevari, S., Formelli, F.: Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br. J. Cancer 84, 1528–1534 (2001)
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K., Kassack, M.U., Osmak, M., Jaehde, U.: Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol. 73, 298–307 (2007)
Prinetti, A., Cao, T., Illuzzi, G., Prioni, S., Aureli, M., Gagliano, N., Tredici, G., Rodriguez-Menendez, V., Chigorno, V., Sonnino, S.: A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells. J. Biol. Chem. 286, 40900–40910 (2011)
Aureli, M., Loberto, N., Lanteri, P., Chigorno, V., Prinetti, A., Sonnino, S.: Cell surface sphingolipid glycohydrolases in neuronal differentiation and aging in culture. J. Neurochem. 116, 891–899 (2011)
Mehlen, P., Rabizadeh, S., Snipas, S.J., Assa-Munt, N., Salvesen, G.S., Bredesen, D.E.: The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395, 801–804 (1998)
Kubbies, M.: Flow cytometric recognition of clastogen induced chromatin damage in G0/G1 lymphocytes by non-stoichiometric Hoechst fluorochrome binding. Cytometry 11, 386–394 (1990)
Overkleeft, H.S., Renkema, G.H., Neele, J., Vianello, P., Hung, I.O., Strijland, A., van der Burg, A.M., Koomen, G.J., Pandit, U.K., Aerts, J.M.: Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273, 26522–26527 (1998)
Wang, P., Zhang, J., Bian, H., Wu, P., Kuvelkar, R., Kung, T.T., Crawley, Y., Egan, R.W., Billah, M.M.: Induction of lysosomal and plasma membrane-bound sialidases in human T-cells via T-cell receptor. Biochem. J. 380, 425–433 (2004)
Prinetti, A., Basso, L., Appierto, V., Villani, M.G., Valsecchi, M., Loberto, N., Prioni, S., Chigorno, V., Cavadini, E., Formelli, F., Sonnino, S.: Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells. J. Biol. Chem. 278, 5574–5583 (2003)
Kolter, T., Sandhoff, K.: Sphingolipids-their metabolic pathways and the pathobiochemistry of nerodegenrative diseases. Angew. Chem. Int. Ed. 38, 1532–1568 (1999)
Goni, F.M., Alonso, A.: Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim. Biophys. Acta 1758, 1902–1921 (2006)
Huschtscha, L.I., Bartier, W.A., Ross, C.E., Tattersall, M.H.: Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br. J. Cancer 73, 54–60 (1996)
Vaidya, J.S., Joseph, D.J., Tobias, J.S., Bulsara, M., Wenz, F., Saunders, C., Alvarado, M., Flyger, H.L., Massarut, S., Eiermann, W., Keshtgar, M., Dewar, J., Kraus-Tiefenbacher, U., Sütterlin, M., Esserman, L., Holtveg, H.M.R., Roncadin, M., Pigorsch, S., Metaxas, M., Falzon, M., Matthews, A., Corica, T., Williams, N.R., Baum, M.: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet. 376, 91–102
Volterrani, F., Aldrighetti, D., Bolognesi, A., Di Muzio, N., Reni, M., Ronzoni, M., Fossati, V., Villa, E., Marassi, A., Veronesi, P., et al.: Analysis of the results of 264 cases of small breast carcinoma treated with conservative surgery and radiotherapy. Radiol Med 82, 322–327 (1991)
Vojtesek, B., Lane, D.P.: Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci. 105(Pt 3), 607–612 (1993)
Ward, J.F.: The complexity of DNA damage: relevance to biological consequences. Int. J. Radiat. Biol. 66, 427–432 (1994)
Coleman, C.N.: Beneficial liaisons: radiobiology meets cellular and molecular biology. Radiother. Oncol. 28, 1–15 (1993)
McMillan, T.J.: Residual DNA damage: what is left over and how does this determine cell fate? Eur. J. Cancer 28, 267–269 (1992)
Hall, E.J.: Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. Int. J. Radiat. Oncol. Biol. Phys. 30, 1019–1028 (1994)
Bedford, J.S.: Sublethal damage, potentially lethal damage, and chromosomal aberrations in mammalian cells exposed to ionizing radiations. Int. J. Radiat. Oncol. Biol. Phys. 21, 1457–1469 (1991)
Harnden, D.G.: The nature of ataxia-telangiectasia: problems and perspectives. Int. J. Radiat. Biol. 66, S13–19 (1994)
Deng, X., Yin, X., Allan, R., Lu, D.D., Maurer, C.W., Haimovitz-Friedman, A., Fuks, Z., Shaham, S., Kolesnick, R.: Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science 322, 110–115 (2008)
Mesicek, J., Lee, H., Feldman, T., Jiang, X., Skobeleva, A., Berdyshev, E.V., Haimovitz-Friedman, A., Fuks, Z., Kolesnick, R.: Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal. 22, 1300–1307
Verheij, M., Bartelink, H.: Radiation-induced apoptosis. Cell Tissue Res. 301, 133–142 (2000)
Chigorno, V., Sciannamblo, M., Mikulak, J., Prinetti, A., Sonnino, S.: Efflux of sphingolipids metabolically labeled with [1-3H]sphingosine, L-[3-3H]serine and [9,10-3H]palmitic acid from normal cells in culture. Glycoconj. J. 23, 159–165 (2006)
Chigorno, V., Tettamanti, G., Sonnino, S.: Metabolic processing of gangliosides by normal and Salla human fibroblasts in culture. A study performed by administering radioactive GM3 ganglioside. J. Biol. Chem. 271, 21738–21744 (1996)
Chigorno, V., Pitto, M., Cardace, G., Acquotti, D., Kirschner, G.N., Sonnino, S., Ghidoni, R., Tettamanti, G.: Association of gangliosides to fibroblasts in culture: A study performed with GM1 [14C]-labelled at the sialic acid acetyl group. Glycoconj. J. V2, 279–291 (1985)
Acknowledgements
This work was supported by grant PRIN (Italy) to S.S.
Conflict of interest
The authors declare that they have no conflict of interest
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aureli, M., Bassi, R., Prinetti, A. et al. Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content. Glycoconj J 29, 585–597 (2012). https://doi.org/10.1007/s10719-012-9385-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10719-012-9385-2